Puppy

Age: <1 Year

Vaccines & Schedules

Vaccine

Age of 1st Dose

Doses in Primary (min interval
between doses)

Booster

Comments

CORE VACCINES

12-16
weeks

1 dose

Annual

Depending on local regulations

Distemper

6-16
weeks

2 doses, 3-4 weeks apart

After 1-yr and then every 3-yr

Included in DAPPV

6-16
weeks

2 doses, 3-4 weeks apart

After 1-yr and then every 3-yr

Included in DAPPV

Infectious canine

hepatitis (canine

adenovirus)

6-18
weeks

2 doses, 3-4 weeks apart

After 1-yr and then every 3-yr

Included in DAPPV

ADDITIONAL VACCINES

6-8 weeks

2-3 doses, 3-4 weeks apart

1-3 years,
depending on
manufacturer

Included in DAPPV

Parenteral
/ oral: >8
weeks
Nasal: >3
weeks

Parenteral: 2 doses,
2-4 weeks apart
Nasal/oral: 1 dose

1 year

Lifestyle vaccine
(boarding/showing)

>9 weeks

2 doses, 3-4 weeks apart

Annual prior to the start of tick season

Only for high-risk areas

>8 weeks

2 doses, 3-4 weeks apart

Once yearly for dogs in high-risk areas

Vaccine is recommended for all dogs as all dogs are at-risk

6-8 weeks

2 doses, 3-4 weeks apart

Annual

For at-risk dogs
Outbreak map

Home Visits Summary

VISIT # 1

6-9 WEEKS; FULL TEAM

Service Provided

Product Info

DA2PP + Leptospirosis vaccine combo

ULTRA DURAMUNE DAP PLUS 4L (Elanco; SQ)
VANGUARD DAPP/L4 (Zoetis; SQ)
NOBIVAC CANINE 1-DAPPV PLUS L4 (Merck; SQ)

IDEXX Fecal Dx® Profile with Giardia (24639)

Drontal Plus

Simparica Trio Chewable Tablets*

1 dose

Microchip placement

Pet Link

Add-ons

Nail Trim

Forti Flora SA Canine Probiotic Supplement

  • DA2PP + Leptospirosis vaccine combo: Elanco’s ULTRA DURAMUNE DAP PLUS 4L and Zoetis’s VANGUARD DAPP/L4 vaccines are labeled for administration for puppies 6 weeks of age or older. Merck’s NOBIVAC CANINE 1-DAPPV PLUS L4 vaccine is labeled for puppies 8 weeks or older.
  • Simparica Trio is labeled for administration to puppies 8 weeks of age or older. An alternative for puppies under 8 weeks of age is Selarid, which is labeled for administration as early as 6 weeks of age for protection against fleas (kills adult fleas & prevents flea eggs from hatching), ticks, heartworm, and ear mites.
  • Drontal Plus (praziquantel/pyrantel pamoate/febantel) is labeled for administration to puppies 3 weeks of age or older.

VISIT # 2

10-13 WEEKS; TECH DRIVEN

Service Provided

Product  Info

DA2PP + Leptospirosis vaccine combo

Same brand as prime

Bordetella + Parainfluenza vaccine

Oral

NOBIVAC Intra-Trac Oral BbPi (Merck)

Bordetella + Parainfluenza vaccine

Intranasal

VANGUARD® RAPID RESP 3 (Zoetis)
NOBIVAC INTRA-TRAC3 (Merck)
BRONCHI-SHIELD III (Elanco)
Recombitek KC2 Vaccine (BI)

Drontal Plus

Simparica Trio Chewable Tablets

1 dose

Add-ons

Nail Trim

VISIT # 3

14-17 WEEKS; FULL TEAM

Service Provided

Product  Info

DA2PP + Leptospirosis vaccine combo

Same brand as prime

Rabies 1-year vaccine

IMRAB 1 (BI)
RABVAC 1 RABIES VACCINE (Elanco)
NOBIVAC RABIES 1 (Merck)
VANGUARD RABIES 1 (Zoetis)

IDEXX Fecal Dx® Profile with Giardia (24639)

Drontal Plus

Simparica Trio Chewable Tablets

1 dose*

Add-ons

Bivalent flu vaccine

VANGUARD CIV H3N2 H3N8 (Zoetis)
NOBIVAC CIV CANINE FLU BIVALENT (Merck)

Lyme vaccine

NOBIVAC LYME (Merck)

DURAMUNE LYME VACCINE (Elanco)
RECOMBITEK LYME (BI)

Nail Trim

Forti Flora SA Canine Probiotic Supplement

DA2PP + Leptospirosis vaccine combo: Puppies under 12 weeks of age should be
revaccinated every 3 to 4 weeks, and the last dose given at or over 16 weeks of age.


● *Home visit schedule change: If lyme and flu vaccines are unnecessary - provide 3 Simparica Trio doses, add anal gland expression and skip Visit #4.

VISIT # 4**

18-21 WEEKS; TECH-DRIVEN

Service Provided

Product Info

Simparica Trio Chewable Tablets

3 doses

Add-ons

Anal gland expression

As needed

Lyme vaccine

Same brand as prime

Bivalent flu vaccine

Same brand as prime

Nail trim

** Only when influenza and lyme vaccines are administered.

VISIT # 5

7 Months or older; TECH-DRIVEN

Service Provided

Product Info

IDEXX Young Wellness with Lab 4Dx® Plus Test (Canine) (26059999)

Chem 10 with IDEXX SDMA® Test, IDEXX CBC®, Lab 4Dx® Plus Test

IDEXX Fecal Ova and Parasites (501)

Simparica Trio Chewable Tablets

6 doses

Dental chews

CET

Add-ons

Nail Trim

Before Your Visit

  • Ahead of Tech-Driven visits, Booking Agents should call the client and (i) make sure the client is aware a tech is coming, and (ii) make sure the pet is “alright” and a vet is not required
  • Have the technician book, in each visit, the following visit (think of commission and how to track), and flag the next visit as “Tech-Driven” or “regular” visit.
  • Booking Agents need to “Flag” the visit, ahead of time, as a “Wellness & Vaccines - Puppy/Kitten”, and confirm post each visit that (i) Technician booked the following visit, as a part of the “Plan” and that the team is aware of the “First Puppy Visit” ahead of the visit (leaving an impression, comprehensive, client education, informing that this is one visit out of 5 - series of vaccinations and so on).

Diagnostics

Prevention is without a doubt the most efficient, cost-effective therapy. Screening and early detection are crucial to minimize morbidity and future healthcare costs. Therefore, comprehensive testing is strongly recommended as a screening tool. See table below for recommended tests by The Vets Internal Medicine expert, Dr. Andrea Johnston.

Test Name

Info

Price

TIER 1

Wellness with Lab 4Dx® Plus Test (Canine) (26059999)

Chem 10 with IDEXX SDMA® Test, IDEXX CBC®, Lab 4Dx® Plus Test

$159.39

IDEXX Fecal Ova and Parasites (501)

$46.80

TIER 2

IDEXX Young Wellness
(28079999)

Chem 10 with IDEXX SDMA® Test, IDEXX CBC®

$97.90

IDEXX Heartworm Antigen by ELISA Add-on - Canine (7231)

$34.78

IDEXX Fecal Ova and Parasites (501)

$46.80

TIER 3

IDEXX Young Preanesthetic
Profile (7839999)

Alkaline phosphatase, ALT (SGPT), BUN, creatinine, glucose, IDEXX SDMA® Test, total protein, IDEXX CBC®

$105.98

IDEXX Heartworm Antigen by ELISA Add-on - Canine (7231)

$34.78

IDEXX Fecal Ova and Parasites (501)

$46.80

Parasiticides

  • Simparica Trio Chewable Tablets is the only broad spectrum single preventative and thus our Tier 1 recommendation. Simparica Trio provides protection from fleas (kills adult fleas and the eggs after they hatch), ticks, heartworm, hookworms and roundworms.
  • In case of known sensitivity to Simparica Trio, the recommended alternative is a combination of Interceptor Plus (puppies 6 weeks of age and older) and Credelio (puppies 8 weeks of age and older). This combination provides protection from fleas, ticks, heartworm, hookworms, roundworms, whipworms and tapeworms.
  • For pets previously positive for whipworm, the combination of Interceptor Plus and Credelio should be recommended. This is due to its high pathogenicity and ability to stay in the ground for a long period of time.

Parasiticides Comparison
Companion Animal Parasite Council (CAPC) Data

Discussion Points for Pet Parents

ASPCA Animal Poison Contral

https://www.aspca.org/pet-care/animal-poison-control

  • If you think your pet may have ingested a potentially poisonous substance, call (888) 426-4435.
  • List of toxic plants with images. Most dangerous toxic plants: Sago palms, azaleas, and rhododendrons.
  • List of toxic human foods. Most dangerous human foods: chocolate, grapes, raisins, onions, garlic, chives, and products containing xylitol sweetener.

Raw food diets

The AVMA and AAHA discourage the feeding of raw animal-source protein due to the high risk of illness to both pets and humans. Pathogens found in raw protein diets can be transmitted to the human population by contact with the food, pet, or environmental surfaces.

Neutering/Spaying

Neutering is associated with a prolonged life expectancy for both sexes compared to their entire
counterparts. This has been reported in multiple studies. In female dogs, neutering reduces or
eliminates the risk of pyometra, a potentially life-threatening condition. Neutering is linked to a
reduced risk of cancer of reproductive organs and heart disease, but an increased risk of joint
disorders and some cancers (lymphoma and hemangiosarcoma) especially in females. [1,2]

Breed Associated Health Risks [1-4]

Health risks by breed can be found at https://www.akc.org/ under the Health link on each breed information page. A handful of larges cale publications on breed related mortality are available.


Brachycephalic (short nosed) breeds

Brachycephalic breeds (French Bulldog, English Bulldog, Pug, and American Bulldog) are predispositions to life-limiting disorders that occur early in life, such as brachycephalic obstructive airway syndrome (BUAS), spinal disease, and dystocia.
Brachycephalic breeds should avoid high temperatures, overexertion, and over-conditioning (obesity). Harnesses rather than collars should be used for leash walks. Pre-emptive surgical intervention to improve upper airway conformation should be recommended before a respiratory crisis occurs.

Deep chested, large and giant breed dogs

Deep chested, large breed dogs (Great Danes, Weimaraners, St. Bernards, Irish setters, Gordon
setters...) are predisposed gastric dilation volvulus (GDV). Pre-emptive gastropexy should be
recommended to reduce the GDV. Feed more than one meal a day and select a dog food with a
low fat and oil content.

Chondrodystrophic breeds

Chondrodystrophic breeds (Dachshund, Pekinese, Beagle, Lhasa Apso) are pre-disposed to
intervertebral disk disease (IVDD). Avoid over-feeding and obesity. Use a harness rather than a
collar for leash walks. Avoid high impact activities like jumping on and off furniture, consider the
use of portable pet stairs.

Congenital cardiovascular disease [5,6]

Many breeds are predisposed to congenital heart disease. If a murmur or arrhythmia is
detected on annual physical exam, a thoracic radiograph or EKG should be pursued. If these are
abnormal, a cardiology referral is recommended. [6, open access journal with helpful diagnostic
flow chart]

  • Aortic Stenosis: Boxers, Golden Retrievers, Rottweilers, German Shepherds, Newfoundlands
  • Pulmonic Stenosis: Boston terriers, Boxers, English Bulldogs, French Bulldogs, Boykin
    Spaniels, Jack Russell Terriers, Keeshonds, terriers
  • Patent Ductus Arteriosus (PDA): Small breed dogs, German Shepherds, Newfoundland
  • Ventricular Septal Defect (VSD): English Springer Spaniels

Congenital kidney disease

  • Renal dysplasia: Alaskan Malamutes, Bedlington Terriers, Chow Chows, Cocker Spaniels, Doberman Pinschers, Keeshonden, Lhasa Apsos, Miniature Schnauzers, Norwegian Elkhounds, Samoyeds, Shih Tzus, Soft-coated Wheaten Terriers, and Standard Poodles o Usually diagnosed via renal ultrasound imaging in juveniles in conjunction with azotemia, isosthenuria.
  • Polycystic kidney disease: Beagles, Bull Terriers, Cairn Terriers, and West Highland White Terrier
    Diagnosis is usually made via renal ultrasound in juveniles
Congenital hepatobiliary disease including vascular anomalies
  • Ductal plate malformations: Boxers
  • Portosystemic vascular malformations (Extravascular portosystemic shunts): Small and Toy breeds (Bichon Frise, Border terriers, Maltese, Yorkshire terriers, Cairn terriers, Havanese, Miniature schnauzer, Silky terriers) should be screened for congenital portosystemic vascular malformations. Large breed dogs (Labrador retrievers, Siberian Husky) occasionally have intrahepatic portosystemic shunts.

    If a paired serum bile acids test is abnormal, submit a protein C level to Cornell Coagulation Laboratory. A protein C less than 70% is consistent with a portosystemic shunt, between 70-99% is in the grey zone, and a value greater than 100% is normal, consistent with microvascular dysplasia. Dogs with a portosystemic shunt should be started on medical management (modified protein diet (Hill’s l/d orRoyal Canin Hepatic, lactulose, and gut flora modulation). A CT angiogram will be needed if surgical shunt attenuation will be pursued or to definitively diagnose dogs in the grey zone. No therapy is needed for dogs with microvascular dysplasia.

Bitesize Mucosal Immunology and Vaccination Routes

Vaccination is an efficient and cost-effective form of infectious disease prevention. Most current vaccines are delivered by injection, which provide systemic protection but partial to no protection at mucosal sites. Considering that >90% of pathogens gain access to the body via mucosal sites, using mucosal vaccination to generate protective immunity at mucosal sites could over-come the limitations of current injection-based vaccines in providing front-line protection against pathogen invasion and dissemination (Holmgren J., Czerkinsky C., 2005; Gerdts V. et al.,2006).

Mucosal tissues (e.g. nasal, oral, ocular, rectal, vaginal) cover a large surface of the body. Since many infections are initiated at mucosal sites, it is critical to develop strategies for neutralising the infectious agent at these surfaces. Mucosal vaccination involves the administration of vaccines at one or more mucosal sites leading to induction of immune responses at the mucosal site of administration, other mucosal sites, and/or systemically.

Immunization involves the delivery of antigens to the mucosal immune system (into
units such as Peyer’s patches in the intestine or the nasal-associated lymphoid tissue in the oropharyngeal cavity). The effector mechanisms for mucosal immune response include the hallmark secretory Immunoglobulin A (SIgA), a protease-resistant antibody and the cell-mediated mucosal immune response. These effectors have been shown to be effective for the clearance of various pathogens including enteric/respiratory viruses and intracellular parasites.

IgA is the first line of defense in the resistance against infection, via inhibiting bacterial and viral adhesion to epithelial cells and by neutralization of bacterial toxins and virus, both extra- and intracellularly. IgA also eliminates pathogens or antigens via an IgA-mediated excretory pathway where binding to IgA is followed by polyimmunoglobulin receptor-mediated transport of immune complexes. SIgA has an important role in mediating the adaptive (antigen specific) humoral (antibody-based) immune defense at mucosal surfaces.

The majority of mucosal vaccines are administered by the oral and nasal routes.
However, not all routes of administration induce an equivalent immune response in terms of potency and longevity, reflecting differences in the organization and cellular make-up of lymphoid structures in different mucosal tissues (Kantele A., et al., 1998; Czerkinsky C., et al., 2012; Czerkinsky C., Holmgren J., 2010).

For example, oral immunization usually stimulates immune responses in the GI tract in
addition to the oral mucosa and nasal-associated lymphoid tissues (NALT) and mammary glands. Intranasal delivery effectively induces antibody production in salivary glands, the NALT and the bronchus-associated lymphoid tissue (BALT) of the lower respiratory tract, and in the urogenital tract. Rectal immunization elicits a more pronounced immune and antibody response in nasal secretions, tears and the rectal mucosa. Thus, depending on the mucosal sites targeted by different pathogens, the route of immunization needs to be care-fully considered (Fujkuyama Y., et al., 2012; Czerkinsky C., Holmgren J., 2010; Saroja C., et al., 2011).

Resources

Sources

1. Teng K.T., Brodbelt D.C., Pegram C., Church D.B., O'Neill D.G. Life tables of annual life expectancy and
mortality for companion dogs in the United Kingdom. Sci Rep. 2022 Apr 28;12(1):6415. doi:
10.1038/s41598-022-10341-6. PMID: 35484374; PMCID: PMC9050668.
2. Urfer, S. R. & Kaeberlein, M. Desexing dogs: A review of the current literature. Animals 9, 1086 (2019).
42.
3. Hart, L. A. & Hart, B. L. An ancient practice but a new paradigm: Personal choice for the age to spay or
neuter a dog. Front. Vet. Sci. 8, 244 (2021).
4. O’Neill, D. G., Church, D. B., McGreevy, P. D., Tomson, P. C. & Brodbelt, D. C. Longevity and mortality of
owned dogs in England. Vet. J. 198, 638–643 (2013).
5. Brambilla P.G., Polli M., Pradelli D., Papa M., Rizzi R., Bagardi M., Bussadori C. Epidemiological study of
congenital heart diseases in dogs: Prevalence, popularity, and volatility throughout twenty years of
clinical practice. PLoS One. 2020 Jul 27;15(7):e0230160. doi: 10.1371/journal.pone.0230160. PMID:
32716943; PMCID: PMC7384636.
6. Saunders AB. Key considerations in the approach to congenital heart disease in dogs and cats. J Small
Anim Pract. 2021 Aug;62(8):613-623. doi: 10.1111/jsap.13360. Epub 2021 Jun 27. PMID: 34180062.

Ask the Board!